192 related articles for article (PubMed ID: 17075466)
1. [Anti-EGFR therapy: towards a "à la carte" targeting of hepatocellular carcinoma].
Fartoux L; Desbois-Mouthon C; Poupon R; Rosmorduc O
Gastroenterol Clin Biol; 2006 Oct; 30(10):1133-5. PubMed ID: 17075466
[No Abstract] [Full Text] [Related]
2. Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy.
Ciardiello F; De Vita F
Prog Drug Res; 2005; 63():93-114. PubMed ID: 16265878
[No Abstract] [Full Text] [Related]
3. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
Ready N
Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
[TBL] [Abstract][Full Text] [Related]
4. Response of malignant thymoma to erlotinib.
Christodoulou C; Murray S; Dahabreh J; Petraki K; Nikolakopoulou A; Mavri A; Skarlos D
Ann Oncol; 2008 Jul; 19(7):1361-1362. PubMed ID: 18534960
[No Abstract] [Full Text] [Related]
5. Medical treatment of non-small-cell lung cancer.
Buter J; Giaccone G
Ann Oncol; 2005; 16 Suppl 2():ii229-32. PubMed ID: 15958463
[No Abstract] [Full Text] [Related]
6. [New biological treatments for lung cancer].
Zalcman G; Richard N; Bergot E
Rev Pneumol Clin; 2007 Feb; 63(1):20-8. PubMed ID: 17457280
[TBL] [Abstract][Full Text] [Related]
7. Targeting EGFR in bilio-pancreatic and liver carcinoma.
Fratto ME; Santini D; Vincenzi B; Silvestris N; Azzariti A; Tommasi S; Zoccoli A; Galluzzo S; Maiello E; Colucci G; Tonini G
Front Biosci (Schol Ed); 2011 Jan; 3(1):16-22. PubMed ID: 21196353
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological background of EGFR targeting.
Castillo L; Etienne-Grimaldi MC; Fischel JL; Formento P; Magné N; Milano G
Ann Oncol; 2004 Jul; 15(7):1007-12. PubMed ID: 15205192
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor inhibition in solid tumours.
Ganti AK; Potti A
Expert Opin Biol Ther; 2005 Sep; 5(9):1165-74. PubMed ID: 16120047
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
Harichand-Herdt S; Ramalingam SS
Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
[TBL] [Abstract][Full Text] [Related]
11. Rationale and clinical validation of epidermal growth factor receptor as a target in the treatment of head and neck cancer.
Caponigro F
Anticancer Drugs; 2004 Apr; 15(4):311-20. PubMed ID: 15057134
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
Metro G; Finocchiaro G; Toschi L; Bartolini S; Magrini E; Cancellieri A; Trisolini R; Castaldini L; Tallini G; Crino L; Cappuzzo F
Rev Recent Clin Trials; 2006 Jan; 1(1):1-13. PubMed ID: 18393776
[TBL] [Abstract][Full Text] [Related]
13. EGFR inhibition as a therapy for head and neck squamous cell carcinoma.
Loeffler-Ragg J; Schwentner I; Sprinzl GM; Zwierzina H
Expert Opin Investig Drugs; 2008 Oct; 17(10):1517-31. PubMed ID: 18808311
[TBL] [Abstract][Full Text] [Related]
14. The role of inhibitors of the epidermal growth factor in management of head and neck cancer.
Brockstein B; Lacouture M; Agulnik M
J Natl Compr Canc Netw; 2008 Aug; 6(7):696-706. PubMed ID: 18691458
[TBL] [Abstract][Full Text] [Related]
15. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.
Höpfner M; Sutter AP; Huether A; Schuppan D; Zeitz M; Scherübl H
J Hepatol; 2004 Dec; 41(6):1008-16. PubMed ID: 15582135
[TBL] [Abstract][Full Text] [Related]
16. [Epidermal growth factor receptors (EGFR): a new target for anticancer therapy].
Gainet M; Guardiola E; Dufresne A; Pivot X
Cancer Radiother; 2003 Jun; 7(3):195-9. PubMed ID: 12834777
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.
Ciardiello F; De Vita F; Orditura M; De Placido S; Tortora G
Expert Opin Emerg Drugs; 2003 Nov; 8(2):501-14. PubMed ID: 14662002
[TBL] [Abstract][Full Text] [Related]
18. [Targeted therapies. New hopes, new challenges].
Barlési F
Rev Mal Respir; 2008 Jun; 25(6):661-2. PubMed ID: 18772823
[No Abstract] [Full Text] [Related]
19. Tumor resensitization to erlotinib following brief substitution of cetuximab.
Epstein RJ; Leung TW
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1111-2. PubMed ID: 18283460
[TBL] [Abstract][Full Text] [Related]
20. Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how?
Juergens R; Brahmer J
Curr Oncol Rep; 2007 Jul; 9(4):255-64. PubMed ID: 17588349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
